Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PULSE BIOSCIENCES, INC.PLSE · Entity 1151 | Chief Financial Officer | February 03, 2025 | August 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PULSE BIOSCIENCES, INC.
Report date February 03, 2025 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.93 · Expires 2035-02-03 | Direct | 300,000 |
Reported balance
After 2025-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-03 · Grant · Acquired 300,000 · Balance 300,000 F1: Half of the shares subject to the option will vest in equal installments on the first, second, third, and fourth anniversaries of the grant date and the remaining shares subject to the option will vest in equal tranches upon the achievement of four performance-based vesting criteria tied to both the Issuer's market capitalization ranging from $2 billion to $5 billion and GAAP revenue targets ranging from $48 million to $175 million, in all cases, subject to the Reporting Person's continued service through each vesting milestone. |
Filing footnotes · ownership attribution and instrument terms
F1: Half of the shares subject to the option will vest in equal installments on the first, second, third, and fourth anniversaries of the grant date and the remaining shares subject to the option will vest in equal tranches upon the achievement of four performance-based vesting criteria tied to both the Issuer's market capitalization ranging from $2 billion to $5 billion and GAAP revenue targets ranging from $48 million to $175 million, in all cases, subject to the Reporting Person's continued service through each vesting milestone.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2025 Filed Aug 28, 2026 19:17 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001437749-26-029220 · rdgdoc.xml · derivative · entry 1 Skinner Jon · CIK 0002078637 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2035-02-03 F1 · derivative.exercise_date: Half of the shares subject to the option will vest in equal installments on the first, second, third, and fourth anniversaries of the grant date and the remaining shares subject to the option will vest in equal tranches upon the achievement of four performance-based vesting criteria tied to both the Issuer's market capitalization ranging from $2 billion to $5 billion and GAAP revenue targets ranging from $48 million to $175 million, in all cases, subject to the Reporting Person's continued service through each vesting milestone. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.